• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Rezlidhia (olutasidenib) capsules

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Rezlidhia (olutasidenib) capsules

  • Profile

Profile

Contact Information

Contact: Rigel Pharmaceuticals
Website: https://www.rezlidhia.com/

Currently Enrolling Trials

    Show More

    General Information

    Rezlidhia (olutasidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor.

    Rezlidhia is specifically indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.

    Rezlidhia is supplied as capsules for oral administration. 

    Select patients based on the presence of IDH1 mutations in blood or bone marrow.

    • The recommended dosage of Rezlidhia is 150 mg taken orally twice daily until disease progression or unacceptable toxicity.
    •  Administer Rezlidhia capsules orally about the same time each day. Do not administer 2 doses within 8 hours. Take on an empty stomach at least 1 hour before or 2 hours after a meal.
    • Swallow Rezlidhia capsules whole. Do not break, open, or chew the capsules. If a dose of Rezlidhia is vomited, do not administer a replacement dose; wait until the next scheduled dose is due. If a dose of Rezlidhia is missed or not taken at the usual time, administer the dose as soon as possible and at least 8 hours prior to the next scheduled dose. Return to the normal schedule the following day.
    • For patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response.

    Mechanism of Action

    Rezlidhia (olutasidenib) is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1). In patients with AML, susceptible IDH1 mutations are defined as those leading to increased levels of 2-hydroxyglutarate (2-HG) in the leukemia cells and where efficacy is predicted by 1) clinically meaningful remissions with the recommended dose of olutasidenib and/or 2) inhibition of mutant IDH1 enzymatic activity at concentrations of olutasidenib sustainable at the recommended dosage according to validated methods. The most common of such mutations in patients with AML are R132H and R132C substitutions. In vitro, olutasidenib inhibited mutated IDH1 R132H, R132L, R132S, R132G, and R132C proteins; wild-type IDH1 or mutated IDH2 proteins were not inhibited. Olutasidenib inhibition of mutant IDH1 led to decreased 2-HG levels in vitro and in in vivo xenograft models.

    Side Effects

    Adverse effects associated with the use of Rezlidhia (olutasidenib) may include, but are not limited to, the following:

    • aspartate aminotransferase increased
    • alanine aminotransferase increased
    • potassium decreased
    • sodium decreased
    • alkaline phosphatase increased
    • nausea
    • creatinine increased
    • fatigue/malaise
    •  arthralgia
    • constipation
    • lymphocytes increased
    • bilirubin increased
    • leukocytosis
    • uric acid increased
    • dyspnea
    •  pyrexia
    • rash
    • lipase increased
    • mucositis
    • diarrhea
    • transaminitis

    Rezlidhia comes with an increased risk of hepatotoxicity. 

    The Rezlidhia (olutasidenib) drug label comes with the following Black Box Warning: • Differentiation syndrome, which can be fatal, can occur with Rezlidhia treatment. • If differentiation syndrome is suspected, withhold Rezlidhia and initiate corticosteroids and hemodynamic monitoring until symptom resolution.

    Clinical Trial Results

    The FDA approval of Rezlidhia was based on data from an open-label Phase 2 registrational study evaluating  Rezlidhia monotherapy at a dose of 150 mg twice daily in 153 patients with mIDH1 R/R AML. The efficacy-evaluable population was 147 patients who initiated  Rezlidhia at least six months prior to the interim analysis cutoff date of June 18, 2021, and who had a centrally confirmed IDH1 mutation. The primary endpoint was a composite of a complete remission (CR) plus a complete remission with partial hematological recovery (CRh). CRh is defined as less than 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets >50,000/microliter and absolute neutrophil count >500/microliter). 

    Results from the trial demonstrated a 35% (51/147) CR+CRh rate in mIDH1 R/R AML patients, with a median duration of response of 25.9 months. The median time to CR or CRh was 1.9 months. Of the patients who achieved the primary endpoint of CR+CRh, 92% (47/51) were CR with a median duration of response of 28.1 months. 

    Approval Date: 2022-12-01
    Company Name: Rigel Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing